A Lower Serum Antioxidant Capacity as a Distinctive Feature for Women with HER2+ Breast Cancer: A Preliminary Study
Authors:
- Letícia L. D. SantosLSLetícia L. D. Santos
- Alinne T. F. SilvaASAlinne T. F. Silva
- Izabella C. C. FerreiraIFIzabella C. C. Ferreira
- Adriele V. SouzaASAdriele V. Souza
- Allisson B. JustinoAJAllisson B. Justino
- Donizeti W. SantosDSDonizeti W. Santos
- Luiz Ricardo GoulartLGLuiz Ricardo Goulart
- Carlos Eduardo PaivaCPCarlos Eduardo Paiva
- Foued S. EspíndolaFoued S. Espíndola
- Yara C. P. MaiaYara C. P. Maia
Open Access
Abstract
The overexpression of HER2 in breast cancer (BC) can contribute to redox imbalance, which is related to damage and structural modification in many biomolecules. To the best of our knowledge, this is the first study that has investigated the infrared spectrum wavenumbers obtained by ATR-FTIR and their relationship with the levels of redox status markers such as reduced glutathione, superoxide dismutase (SOD), catalase, Ferric Reducing Antioxidant Power (FRAP), and protein carbonyl among women with HER2+ BC, HER2− BC, and benign breast disease (BBD). The study was conducted with 25 women, 17 of whom were diagnosed with BC (6 HER2+ and 11 HER2−) and 8 with BBD. Our results indicate HER2+ BC cases could be distinguished from HER2− BC and BBD cases by their serum’s antioxidant capacity [HER2+ BC vs. HER2− BC (AUC = 0.818; specificity = 81.82%; sensitivity = 66.67%); HER2+ BC vs. BBD (AUC = 0.875; specificity = 75%; sensitivity = 83.33%)]. The changes in biochemical terms that occur in serum as a result of the scarcity of antioxidants are related to a peculiar fingerprint in the infrared spectrum obtained by ATR-FTIR. In the serum of women with BBD, the SOD enzyme level is the highest, and this characteristic allowed us to distinguish them from HER2− BC. Finally, data regarding the serological antioxidant capacity of FRAP and the infrared spectrum by ATR-FTIR will allow us to assess biochemical changes that occur before clinical signs, indicating whether changes in therapy or interventions are necessary.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (409482/2021-8)
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (APQ-01339-21)
- CAPES and National Institute of Science and Technology in Teranostics and Nanobiotechnology–INCT–Teranano
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais–FAPEMIG (REMITRIBIC, RED-00031-21)
This publication has 62 references indexed in Scilit:
- Manganese Superoxide Dismutase Is a p53-Regulated Gene That Switches Cancers between Early and Advanced StagesCancer Research, 2011
- Heterogeneity in breast cancerJournal of Clinical Investigation, 2011
- Experimental Evidence that Methylmalonic Acid Provokes Oxidative Damage and Compromises Antioxidant Defenses in Nerve Terminal and Striatum of Young RatsCellular and Molecular Neurobiology, 2011
- C-junInhibits Mammary Apoptosis In VivoMolecular Biology of the Cell, 2010
- Diagnosis of breast cancer with infrared spectroscopy from serum samplesVibrational Spectroscopy, 2010
- High levels of oxidative stress in patients with advanced lung cancerRespirology, 2008
- Infrared spectroscopy of proteinsBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2007
- 2D-FT-IR spectrometry: a new tool for the analysis of stress-induced plasma content changesVibrational Spectroscopy, 2003
- Applications of FT-IR spectrometry to plasma contents analysis and monitoringVibrational Spectroscopy, 2003
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991